NOVN - Mergers and acquisitions

– Novan is a fully integrated pharmaceutical company with proven capabilities across drug development through to commercialization – – EPI Health adopts Novan corporate branding, creating unified identity in advance of potential commercial launch of berdazimer gel, 10.3% (SB206) – DURHAM, N.C., March 08, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced that its commercial subsidiary, EPI Health, will now unify under one brand name, Novan. "Since the closing of our acquisition of EPI Health in March of 2022, we have made significant progress integrating our organizations into one cohesive business. As of today, we are pleased to move forward

– Potential FDA approval anticipated in first quarter 2024, assuming the filing is accepted by the FDA and under standard review timelines – – Molluscum contagiosum is a viral skin infection that affects approximately 6 million people, most of them children1,2 – – Berdazimer gel, 10.3% has the potential to be the first FDA-approved prescription product for the treatment of molluscum3 – DURHAM, N.C., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), announced today that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking marketing approval for berdazimer gel, 10.3% (SB206) for the topical trea

DURHAM, N.C., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced that EPI Health, LLC, a fully consolidated subsidiary of Novan, has entered into an exclusive license agreement with Sato Pharmaceutical Co., Ltd. ("Sato") granting Sato the right to develop, manufacture and market RHOFADE® (oxymetazoline hydrochloride 1% cream) for rosacea in Japan. "Since 2017, our relationship with Sato has been a valuable component of our strategy and we are pleased to further deepen and expand our partnership with Sato through this license agreement. We are committed to growing our revenue-generating product portfolio and believe the expansion of ou

– Agreement provides immediate access to cash flow – – EPI Health leveraging accounts receivables from commercial product sales to bolster working capital needs – DURHAM, N.C., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced that EPI Health, LLC, a fully consolidated subsidiary of the Company, has signed an accounts receivable-backed factoring agreement, to support its operations, with Bay View Funding, a wholly owned subsidiary of Heritage Bank of Commerce (NASDAQ:HTBK). "This arrangement with Bay View is another source of non-dilutive funding that enables us to manage our working capital in a way that will help our consolidated

DURHAM, N.C. and COPENHAGEN, Denmark, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), EPI Health, a Novan Company, and MC2 Therapeutics today announced that data from a 17-question survey sponsored by the Company was published in a poster entitled, "Improving Patient Acceptability and Adherence in Psoriasis Treatment," at the 42nd Annual Fall Clinical Dermatology Conference® taking place October 20-23, 2022, in Las Vegas, NV. "Topical medications continue to be a mainstay of psoriasis treatment and results from this survey provide valuable insights into what attributes patients value in these medications. This is important because treatment expe

DURHAM, N.C. and COPENHAGEN, Denmark, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), EPI Health, a Novan Company, and MC2 Therapeutics today announced positive data demonstrating the impact of PAD Technology™ in WYNZORA® Cream in three posters featured at the 42nd Annual Fall Clinical Dermatology Conference® taking place October 20-23, 2022, in Las Vegas, NV. PAD Technology™, as explained in one of the posters, is a proprietary topical formulation and drug delivery system that allows CAL and BDP to co-exist in an aqueous environment (WYNZORA® Cream), for the first time.1 These active ingredients are stable at different pH levels, and without the un

DURHAM, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) and EPI Health, a Novan Company, today announced that eight abstracts have been accepted for poster presentation at the 42nd Annual Fall Clinical Dermatology Conference® being held October 20-23, 2022, in Las Vegas, NV. Details for the poster presentations are as follows, which can be viewed at any time during the conference: Title: Patient and Caregiver Experiences with Molluscum Contagiosum: Results from an Exit Interview Conducted with B-SIMPLE4 Study ParticipantsAuthors: John C. Browning, MD, Martina Cartwright, PhD, Ira Thorla, Jr, MD, Susan A. Martin, MSPH, Oyebimpe Olayinka-Amao,

– New data analysis from previously completed successful Phase 3 study1 demonstrated WYNZORA® Cream to be effective and convenient for skin of color patients for the treatment of plaque psoriasis DURHAM, N.C. and COPENHAGEN, Denmark, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced that EPI Health, a Novan Company, and MC2 Therapeutics presented data from a previously unpublished subgroup analysis of the U.S. Phase 3 pivotal study of WYNZORA® Cream at the Skin of Color Update 2022 Conference held September 9-11, 2022, in New York, NY. Published as a poster, this analysis from a previously completed Phase 3 randomized

– The B-SIMPLE4 pivotal Phase 3 clinical study of berdazimer gel, 10.3% (SB206) is the largest interventional trial of molluscum contagiosum ("molluscum") (n=891)1 – – Company previously reported positive topline efficacy and favorable safety data at Week 12 from B-SIMPLE 4 in June 2021, achieving statistical significance for the primary endpoint with p-value less than 0.0001 and no serious adverse events related to treatment with berdazimer gel, 10.3% – – There are currently no FDA approved prescription therapies available for the treatment of molluscum, a viral skin infection that impacts as many as 6 million people each year, mostly children2,3 – DURHAM, N.C., July 13, 2022 /PRNewswire/ -

– Based on clinical data from previously completed B-SIMPLE4 pivotal Phase 3 clinical study, berdazimer gel, 10.3% (SB206) can shorten the duration of molluscum infection and increase the chance of clearance by enhancing inflammation of molluscum – – Currently no FDA-approved prescription therapies for the treatment of molluscum – – Novan advancing berdazimer gel, 10.3% toward New Drug Application (NDA) submission for molluscum contagiosum, targeted before end of 2022 DURHAM, N.C., May 19, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN), today announced it will present Beginning of The End (BOTE) clinical data from its previously completed Phas